Table of Contents
Pathology Research International
Volume 2012, Article ID 947041, 7 pages
http://dx.doi.org/10.1155/2012/947041
Clinical Study

The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma

1Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
2Department of Surgery, Loyola University Medical Center, Maywood, IL 60153, USA

Received 21 November 2011; Accepted 1 January 2012

Academic Editor: P. J. Van Diest

Copyright © 2012 Melike Pekmezci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Viale, M. M. Regan, E. Maiorano et al., “Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3846–3852, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. D. C. Allred, J. M. Harvey, M. Berardo, and G. M. Clark, “Prognostic and predictive factors in breast cancer by immunohistochemical analysis,” Modern Pathology, vol. 11, no. 2, pp. 155–168, 1998. View at Google Scholar · View at Scopus
  3. S. K. Mohsin, H. Weiss, T. Havighurst et al., “Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study,” Modern Pathology, vol. 17, no. 12, pp. 1545–1554, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. Stendahl, L. Rydén, B. Nordenskjöld, P. E. Jönsson, G. Landberg, and K. Jirström, “High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients,” Clinical Cancer Research, vol. 12, no. 15, pp. 4614–4618, 2006. View at Publisher · View at Google Scholar · View at PubMed
  5. O. Abe, R. Abe, K. Enomoto et al., “Tamoxifen for early breast cancer: an overview of the randomised trials,” The Lancet, vol. 351, no. 9114, pp. 1451–1467, 1998. View at Publisher · View at Google Scholar
  6. S. Paik, R. Hazan, E. R. Fisher et al., “Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer,” Journal of Clinical Oncology, vol. 8, no. 1, pp. 103–112, 1990. View at Google Scholar · View at Scopus
  7. M. F. Press, L. Bernstein, P. A. Thomas et al., “HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas,” Journal of Clinical Oncology, vol. 15, no. 8, pp. 2894–2904, 1997. View at Google Scholar · View at Scopus
  8. M. De Laurentiis, G. Arpino, E. Massarelli et al., “A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer,” Clinical Cancer Research, vol. 11, no. 13, pp. 4741–4748, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. C. L. Vogel, M. A. Cobleigh, D. Tripathy et al., “Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 719–726, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. A. C. Wolff, M. E. H. Hammond, J. N. Schwartz et al., “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer,” Archives of Pathology and Laboratory Medicine, vol. 131, no. 1, pp. 18–43, 2007. View at Google Scholar · View at Scopus
  11. M. E. H. Hammond, D. F. Hayes, M. Dowsett et al., “American Society of Clinical oncology/college of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer,” Archives of Pathology and Laboratory Medicine, vol. 134, no. 6, pp. 907–922, 2010. View at Google Scholar · View at Scopus
  12. G. Uy, A. Laudico, J. Carnate Jr. et al., “Breast cancer hormone receptor assay results of core needle biopsy and modified radical mastectomy specimens from the same patients,” Clinical Breast Cancer, vol. 10, no. 2, pp. 154–159, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. G. B. Mann, V. D. Fahey, F. Feleppa, and M. R. Buchanan, “Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5148–5154, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. S. C. Young, R. J. Burkett, and C. Stewart, “Discrepancy in ER levels of breast carcinoma in biopsy vs mastectomy specimens,” Journal of Surgical Oncology, vol. 29, no. 1, pp. 54–56, 1985. View at Google Scholar · View at Scopus
  15. I. Teicher, M. A. Tinker, and L. J. Auguste, “Effect of operative devascularization on estrogen and progesterone receptor levels in breast cancer specimens,” Surgery, vol. 98, no. 4, pp. 784–791, 1985. View at Google Scholar · View at Scopus
  16. J. S. Meyer, K. Schechtman, and R. Valdes Jr., “Estrogen and progesterone receptor assays on breast carcinoma from mastectomy specimens,” Cancer, vol. 52, no. 11, pp. 2139–2143, 1983. View at Google Scholar · View at Scopus
  17. J. Hasson, P. A. Luhan, and M. W. Kohl, “Comparison of estrogen receptor levels in breast cancer samples from mastectomy and frozen section specimens,” Cancer, vol. 47, no. 1, pp. 138–139, 1981. View at Google Scholar · View at Scopus
  18. L. M. Ellis, J. L. Wittliff, M. S. Bryant et al., “Lability of steroid hormone receptors following devascularization of breast tumors,” Archives of Surgery, vol. 124, no. 1, pp. 39–42, 1989. View at Google Scholar · View at Scopus
  19. N. S. Goldstein, M. Ferkowicz, E. Odish, A. Mani, and F. Hastah, “Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma,” American Journal of Clinical Pathology, vol. 120, no. 1, pp. 86–92, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. T. Khoury, S. Sait, H. Hwang et al., “Delay to formalin fixation effect on breast biomarkers,” Modern Pathology, vol. 22, no. 11, pp. 1457–1467, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. Qiu, S. Kulkarni, R. Chandrasekhar et al., “Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones,” American Journal of Clinical Pathology, vol. 134, no. 5, pp. 813–819, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. R. Bhargava, N. N. Esposito, and D. J. Dabbs, “Immunohistology of the breast,” in Diagnostic Immunohistochemistry Theranostic and Genomic Applications, D. J. Dabbs, Ed., pp. 763–819, Elsevier Saunders, Philadelphia, Pa, USA, 3rd edition, 2010. View at Google Scholar
  23. S. Apple, R. Pucci, A. C. Lowe, I. Shintaku, S. Shapourifar-Tehrani, and N. Moatamed, “The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma,” American Journal of Clinical Pathology, vol. 135, no. 4, pp. 592–598, 2011. View at Publisher · View at Google Scholar · View at PubMed
  24. A. C. Lowe, G. Nanjangud, I. Shintaku et al., “Effect of ischemic time, fixation time and fixatives on Her-2/Neu IHC and FISH results in breast cancer,” Modern Pathology, vol. 24, supplement 1, 59A-Abstract 206, 2011. View at Google Scholar
  25. B. Portier, E. Downs-Kelly, J. Rowe et al., “Cold ischemia time: effect on HER2 detection by In-Situ hybridization and immunohistochemistry,” Modern Pathology, vol. 24, supplement 1, 52A-Abstract 206, 2011, Abstract No. 236. View at Google Scholar
  26. T. W. Jacobs, J. E. Prioleau, I. E. Stillman, and S. J. Schnitt, “Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer,” Journal of the National Cancer Institute, vol. 88, no. 15, pp. 1054–1059, 1996. View at Google Scholar · View at Scopus
  27. M. Mirlacher, M. Kasper, M. Storz et al., “Influence of slide aging on results of translational research studies using immunohistochemistry,” Modern Pathology, vol. 17, no. 11, pp. 1414–1420, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. D. M. Barnes, R. R. Millis, L. V. A. M. Beex, S. M. Thorpe, and R. E. Leake, “Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance,” European Journal of Cancer, vol. 34, no. 11, pp. 1677–1682, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Paik, C. Kim, and N. Wolmark, “HER2 status and benefit from adjuvant trastuzumab in breast cancer,” The New England Journal of Medicine, vol. 358, no. 13, pp. 1409–1411, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus